Fig. 2
From: Effects of antivirals on patients with COVID-19 breakthrough
Effects of antivirals on the risks of residual respiratory symptoms (primary outcome) and long COVID-19 (secondary outcome)
Abbreviation: CI: confidence interval; SoC: standard of care
Note: Reference level of the exposure was SoC. Reference levels of the primary and secondary outcomes were symptom-free status within ≤ 7 days and no signs/symptoms of long COVID-19, respectively. Panel A: primary analysis. Panel B: sensitivity analysis. Adjusted estimates were controlled for gender, age, weight, height, comorbidities, and concurrent medications